Cytiva develops two new protein A resins bringing cost efficiency to mAb capture
April 24, 2025 | Thursday | News
Cytiva's expanded resin portfolio will support advances in the mAb and biosimilar markets
With the growth and transformation of the monoclonal antibody (mAb) market, particularly with the recent rapid rise of biosimilars, a one-size-fits-all approach to protein purification is no longer viable.
To address this, Cytiva developed two new protein A resins: the MabSelect SuRe 70 and the MabSelect PrismA X.
Sofie Stille, Vice President and General Manager, Resins and Technologies, Cytiva, says: “The different stages of drug development require different purification needs. As more molecules are being brought to clinic, we wanted to provide our customers with innovative and cost-effective options regardless of stage. These new resins offer affordability without sacrificing quality.”
With these new resins, Cytiva has expanded its comprehensive protein A resin portfolio with additional options to further help customers reduce manufacturing expenses and increase flexibility, while maintaining the same high-quality customers expect.
MabSelect SuRe 70 has high dynamic binding capacity (DBC). It combines Cytiva’s industry-leading quality with affordability, addressing the needs of clinical stages. While MabSelect PrismA Xoffers highest DBC of all MabSelect resins and excellent durability for robust mAb capture.
The need for affordability is especially relevant in the purification stage for preclinical or clinical production, where 20 batches are run at most. Whereas in commercial production, speed and performance becomes crucial.
Manoj Kumar R Panicker, General Manager at Cytiva India, states: “Our top priority is addressing our customers' needs for productivity and speed to market. With the rapid growth of our Indian customer base, these two products are designed to assist at any stage or scale, offering tailored solutions that excel in speed, performance, and affordability, all with a commitment to sustainability.”
